| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Deutetrabenazine is the first deuterated drug to receive Food and Drug Administration approval. This deuterated form of the drug tetrabenazine is indicated for the treatment of chorea associated with Huntington's disease as well as tardive dyskinesia. Ongoing clinical trials suggest that a number of other deuterated compounds are being evaluated for the treatment of human diseases and not merely as research tools.[1]
|
|---|---|
| ln Vivo |
Capsaicin inhibits lung cancer development by altering protein expression of apoptosis regulators p53, Bcl-2, Bax, and caspase-3[3]. Capsaicin (2 μg per mouse, 40 μL, injected into the plantar surface of the left hind paw) induces pain-related behaviors in mice[5]. Capsaicin (3-30 μg in 10 μL per rat, injected into the plantar surface) induces secondary mechanical hypersensitivity (SMH) in rats (a model used clinically as a potential predictive model of neuropathic pain)[6]. Capsaicin (0-500 μg in 25 μL per rat, injected subcutaneously into the center of the right whisker pad) induces pain in the orofacial region of rats[7]. At high doses, capsaicin may need to be administered under anesthesia[8][9]. Capsaicin is more pungent than dihydrocapsaicin[10]. Note: The spicy taste is choking, please be aware.
|
| References |
| Molecular Formula |
C18H20D7NO3
|
|---|---|
| Molecular Weight |
312.46
|
| Related CAS # |
Capsaicin;404-86-4
|
| Synonyms |
Capsaicin-d7; (E)-Capsaicin-d7
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2004 mL | 16.0020 mL | 32.0041 mL | |
| 5 mM | 0.6401 mL | 3.2004 mL | 6.4008 mL | |
| 10 mM | 0.3200 mL | 1.6002 mL | 3.2004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
